May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...

September 10, 2009 — There are now published data from a phase 2 multicenter trial on the effectiveness of bevacizumab (Avastin, Genentech) in patients with glioblastoma who have progressed despite ...

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study The Avastin in Glioblastoma trial has shown that patients ...

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK) The use of bevacizumab in ...

LOS ANGELES, May 15 (Reuters) - Results from a mid-stage trial showed treatment with Genentech Inc's Avastin improved survival for patients with recurring brain cancer, the company said on Thursday.

ZURICH, May 6 (Reuters) - The U.S. Food and Drug Administration has granted accelerated approval for Roche Holding's Avastin drug for the most aggressive form of brain cancer, Roche said on Wednesday.

Half of patients with GBM present with headaches at diagnosis, which is attributed to increases in intracranial pressure (Table 2). 11 Papilledema, now rarely seen because imaging is typically ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...